A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

Penn's leading scientists in CAR-T and mRNA, Carl June and Drew Weissman, are among the company's founders.

In healthy adults, a single low dose of IMP761 continues to be safe and appears to reduce the activity of T-cells, a clinical ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...

Researchers use targeted lipid nanoparticles loaded with mRNA to reprogram T cells to fight autoimmune diseases ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer ...

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.